✦ LIBER ✦

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

✍ Scribed by S. Kumar; J. Mikhael; M. Lacy; B. LaPlant; F. Buadi; D. Dingli; M. Gertz; T. Miceli; L. Bergsagel; S. Hayman; C. Reeder; K. Stewart; A. Dispenzieri; D. Gastineau; J. Winters

Book ID: 116282953
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 18
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2011.12.129

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a phase I/II trial adding car

Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation

✍ Comenzo, R L; Hassoun, H; Kewalramani, T; Klimek, V; Dhodapkar, M; Reich, L; Ter 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 128 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

Melphalan 180mg/m2 Can Be Safely Adminis

Melphalan 180mg/m2 Can Be Safely Administered as Conditioning Regimen Prior to an Autologous Stem Cell Transplantation in Multiple Myeloma Patients with Creatinine Clearance ≤60ml/min/1.73 m2 with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

✍ M.H. Abidi; R. Agarwal; N. Tageja; L. Ayash; M. Ventimiglia; A. Deol; Z. Al-Kadh 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Multicenter randomized phase II trial of

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia

✍ Archimbaud, E; Jehn, U; Thomas, X; De Cataldo, F; Fillet, G; Belhabri, A; Peaud, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB